key: cord-0818970-40qgmbxg
authors: Marcello, Alessandro; Civra, Andrea; Bonotto, Rafaela; Nascimento, Lais Alves; Rajasekharan, Sreejith; Giacobone, Chiara; Caccia, Claudio; Cavalli, Roberta; Adami, Marco; Brambilla, Paolo; Lembo, David; Poli, Giuseppe; Leoni, Valerio
title: THE CHOLESTEROL METABOLITE 27-HYDROXYCHOLESTEROL INHIBITS SARS-CoV-2 AND IS MARKEDLY DECREASED IN COVID-19 PATIENTS
date: 2020-08-10
journal: Redox Biol
DOI: 10.1016/j.redox.2020.101682
sha: b7d250c35c28644fc47ce18fb21bd8534d105353
doc_id: 818970
cord_uid: 40qgmbxg

There is an urgent need to identify antivirals against the coronavirus SARS-CoV-2 in the current COVID-19 pandemic and to contain future similar emergencies early on. Specific side-chain cholesterol oxidation products of the oxysterols family have been shown to inhibit a large variety of both enveloped and non-enveloped human viral pathogens. Here we report on the in vitro inhibitory activity of the redox active oxysterol 27-hydroxycholesterol against SARS-CoV-2 and against one of the common cold agents HCoV-OC43 human coronavirus without significant cytotoxicity. Interestingly, physiological serum levels of 27-hydroxycholesterol in SARS-CoV-2 positive subjects were significantly decreased compared to the matched control group, reaching a marked 50% reduction in severe COVID-19 cases. Moreover, no correlation at all was observed between 24-hydroxycholesterol and 25-hydroxycholesterol serum levels and the severity of the disease. Opposite to that of 27-hydroxycholesterol was the behaviour of two recognized markers of redox imbalance, i.e. 7-ketocholesterol and 7β-hydroxycholesterol, whose serum levels were significantly increased especially in severe COVID-19. The exogenous administration of 27-hydroxycholesterol may represent in the near future a valid antiviral strategy in the worsening of diseases caused by present and emerging coronaviruses.

The present COVID-19 pandemic caused by the coronavirus SARS-CoV-2 is yet another example of the dramatic impact of emerging viral infections on human morbidity and mortality worldwide.

Currently, no specific drug for the new coronavirus is available and repurposing is the only strategy in place [1] . Clearly, there is an urgent need for drugs active against a wider number of viruses to contain future emergencies early on. Host directed therapy aims at targeting essential host factors for viral replication and triggering immune antiviral pathways [2] . Advantages of this approach include not only the possibility of targeting multiple viruses, but also an increased threshold to the emergence of resistance.

Selective cholesterol oxidation products, of the oxysterol family, which are ligands of Liver X Receptors (LXRs), have a well-recognized immunomodulatory role [3, 4] . Oxysterols such as 25hydroxycholesterol (25OHC) have shown to markedly inhibit the replication of a large variety of both enveloped and non-enveloped human viral pathogens [5] [6] [7] . However, another oxysterol of enzymatic origin, namely 27-hydroxycholesterol (27OHC), is gaining increasing consideration as a protective molecule not only against the respiratory virus Rhinovirus, but also against a wide range of other viral infections [8] [9] [10] [11] . There is clear evidence that exogenously added 27OHC accumulates in plasma membrane lipid rafts, likely affecting viral entry but also modulating cell signaling stemming from such microdomains [12, 13] .

Both 25OHC and 27OHC are side-chain oxysterols physiologically present in human peripheral blood, cerebrospinal fluid [14, 15] , colostrum and milk [16] . 27OHC is constitutively the J o u r n a l P r e -p r o o f most abundant oxysterol in these biological fluids and present in various tissues and organs, being synthesized by the ubiquitous mitochondrial enzyme 27-cholesterol hydroxylase (Cyp27A1) [15] .

Due to the emerging role of 27OHC as a broad-spectrum antiviral, we deemed relevant to investigate whether it could inhibit SARS-CoV-2 and other coronaviruses. Here we report on the in vitro antiviral activity of 27OHC against SARS-CoV-2 and the human coronavirus HCoV-OC-43.

Moreover, we analyzed the serum levels of 27OHC in 123 healthy individuals, in 27 pauci-or asymptomatic SARS-CoV-2 positive subjects (PACP) and in 117 COVID-19 patients and found quite a marked decrease of the oxysterol in COVID-19 patients that correlates with the severity of the disease. Another notable finding was the increase of serum 7-ketocholesterol and 7 βhydroxycholesterol, two reliable markers of tissue oxidative imbalance, in moderate and severe COVID-19 patients.

The oxysterol 27OHC complexed with 2-hydroxypropyl-β-cyclodextrin (2HP-βCD:27OHC) was kindly provided by Panoxyvir Ltd (Turin, Italy). The anti-RSV monoclonal antibody Ab35958 was purchased from Abcam (Cambridge, United Kingdom). The secondary antibody peroxidaseconjugated AffiniPure F(ab')2 Fragment Goat Anti-Mouse IgG (H+L) was purchased from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA, USA). The recombinant antibody mSIP-3022 against SARS-CoV-2 Spike was previously described [17] .

Vero E6 cells (African green monkey kidney cells) (ATCC®-1586) and human hepatocarcinoma SARS-CoV-2 isolate ICGEB_FVG_S5 was obtained at ICGEB as previously described [18] . Plaque assay was performed by incubating dilutions of SARS-CoV-2 on Vero E6 monolayers at 37 °C for 1 hour. These were then washed with phosphate buffered saline (PBS) and overlaid with DMEM 2% FBS containing 1.5% carboxymethylcellulose for 3 days. Cells were then fixed with 3.7% paraformaldehyde (PFA) and stained with crystal violet 1%.

Human coronavirus strain OC43 (HCoV-O43) (ATCC® VR-1558) was purchased from ATCC (American Type Culture Collection, Rockville, MD, USA) and propagated in MRC-5 cells, at 33°C, in a humidified 5% CO2 incubator. When the full cytopathic effect (CPE) developed, cells and supernatants were harvested, pooled, frozen, and thawed three times, then clarified and aliquoted. The virus was stored at -70°C. CoV titers were determined by the standard plaque method. Briefly, MRC-5 cells were seeded 2 days before infection in 96-well plates, reaching 60%-70% confluence at the time of infection. The viral suspension was serially diluted in DMEM supplemented with 2% fetal bovine serum and inoculated; the infected wells were incubated at 33°C for 1 hour, allowing viruses to attach and enter the cells. After this time, cells were washed with medium, and overlaid with a 1:1 combination of 1.6% SeaPlaque Agarose (BioWhittaker Molecular Applications) and 2× DMEM medium (Gibco BRL) as described elsewhere [8] . The plates were incubated at 33°C for 3 days. After incubation, the plates were fixed and stained as described elsewhere [8] , and the number of plaques formed was counted; viral titers were expressed in terms of plaque forming units per ml (PFU/ml). Respiratory syncytial virus (RSV) strain A2 (ATCC VR-1540) was propagated in Hep-2 and titrated by the indirect immunoperoxidase staining procedure as described elsewhere [19] . Viral titers were expressed as focus-forming unit (FFU) per ml. Viruses were stored at -80°C.

We consecutively included in this study 144 adults with SARS-CoV-2 infection confirmed through real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays of nasal and pharyngeal swabs, in accordance with WHO guidance [20] [21] [22] . RT-PCR was performed at San Gerardo Hospital, Monza, and subsequently at the Italian National Institute of Health, Rome, Italy. 

Basic information such as age, gender, comorbidities, clinical and laboratory data, chest radiograph (when performed), and outcome (survival or non-survival) was obtained from the electronic medical records of each patient and stored by a password-protected database.

The antiviral activity was determined by the plaque reduction assay. For SARS-CoV-2 experiments, Vero E6 cells were seeded in a 48 well plate, at 6 × 10 4 cells/well density and incubated at 37°C overnight. For HCoV-OC43 and RSV, MRC-5 or Hep-2 cells, respectively were first seeded (at 2 × 

Approximately 10 5 PFU of HCoV-OC43 were incubated with a concentration of 2HP-βCD:27OHC corresponding to EC 90 in the antiviral assay. The HCoV-OC43/2HP-βCD:27OHC mixture was incubated for 1h at 33°C. A control experiment by treating the viral suspension with the blank J o u r n a l P r e -p r o o f formulation (2HP-βCD) was also performed. After the incubation, both treated and untreated viruses were titrated to the non-inhibitory concentration of 2HP-βCD:27OHC and the residual viral infectivity was determined by plaque counting. Statistical analysis was performed using One-Way Analysis of Variance (ANOVA), followed by Bonferroni post-hoc test. Significance was reported for p-value <0.05.

The cytotoxicity assay was conducted with Alamar Blue (Invitrogen) as recommended by the manufacturer's protocol. Vero E6 cells were seeded at 1x10 4 

All clinical laboratory measurements were performed in the course of hospitalization. Count blood cells was performed on whole blood with K3-EDTA vacuum tubes and obtained by Sysmex XN-9000 platform (Sysmex, Germany). Blood chemistries were performed on serum vacuum tubes using COBAS 8000 platform (Roche Diagnostics, Germany). Gas chromatography mass spectrometry (GC-MS) analysis was performed on a GC equipped with an Elite column (30 m×0.32 mmid×0.25 mm film; Perkin Elmer, USA) and injection was performed in splitless mode and using helium (1 ml/min) as a carrier gas. The temperature program was as follows: initial temperature of 180 °C was held for 1 min, followed by a linear ramp of 20 °C/min to 270°C, and then a linear ramp of 5°C/min to 290°C, which was held for 10 min.

The mass spectrometer operates in the selected ion-monitoring mode. Peak integration is performed manually, and sterols are quantified from selected-ion monitoring analysis against internal standards J o u r n a l P r e -p r o o f using standard curves for the listed sterols. Additional qualifier (characteristic fragment ions) ions were used for structural identification.

Inter-assay CV ranged between 2.3% for lathosterol and up to 5.3% for 25hydroxycholesterol. Recovery ranged from 97 up to 104% (5-7).

Continuous variables were expressed as mean ± SD, median, interquartile ranges (IQR), min-max range and compared with the ANOVA or Mann-Whitney U test when non parametric distributed.

The study was approved by the Ethical Committee of the Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Roma and stemmed as a sub-project of the Observational cohort study on the natural history of hospitalized SARS-COV-2 patients: the STORM trial of the University of Milano Bicocca, Milan, Italy.

The activity of 27OHC against SARS-CoV-2 and HCoV-OC43, was assessed on Vero-E6 and MRC-5 cells, respectively. To improve its solubility and stability, 27OHC was complexed with 2hydroxypropyl-β-cyclodextrin, a carrier commonly used in drug formulations. Therefore, the complex (2HP-βCD:27OHC) and the carrier alone (2HP-βCD) were tested in parallel to rule out any contribution of the carrier to the antiviral activity. With regard to the standard laboratory parameters measured only in the hospitalized patients (see table 3 ), HB and HCT, already below the normal values, were significantly lower in severe COVID-19 compared to moderate COVID-19 (P = 0.04 for both). Also serum creatinine was increased both in moderate and severe patients, being significantly higher in the severe COVID-19 group as compared to the moderate COVID-19 one (P = 0.03). Alanine Aminotransferase (ALT) and Lactate Dehydrogenase (LDH) were moderately above the normal range, while Creatine Kinase (CK) was much higher respect to the normal values, in all cases without significant difference between the two groups of patients. C Reactive Protein (CRP), resulted to be markedly elevated in COVID-19 with a tendency to increase in the severe cases, and Procalcitonin (PCT), a marker of sepsis, showed a net average increase in the severe COVID-19 group, that however did not reach statistical significance.

The main objective of this observational cohort study was indeed the evaluation of the trend of serum 27OHC concentration in hospitalized moderate and severe COVID-19 patients as well as in PACP versus a control group, but a prior overall look at cholesterol metabolism was deemed essential. Of note, serum concentration of cholesterol and precursor sterols lanosterol, desmosterol (Bloch pathway of cholesterol synthesis) and lathosterol (Kandutsch-Russell pathway of cholesterol synthesis) were all significantly reduced in both moderate and severe COVID-19 patients in comparison to controls (P<0.001) ( figure 4 and table S1 ).

The PACP group showed a cholesterol metabolism picture quite similar to that of the control group, with just a modest but significant reduction in cholesterol and lanosterol serum levels ( figure   4 ).

By far, the most interesting finding of the cohort study was the marked reduction of serum 27OHC in both moderate and severe COVID-19 patients compared to controls (P<0.001 for both) ( figure 5 and table S1).

Actually, the serum 27OHC was already significantly reduced in the PACP group, the mean 27OHC decrease being of 17% in PACP group, 30% in the moderate and of 50% in the severe COVID-19 group (figure 5). The PACP group was in between controls and COVID groups ( figure   5 and table S1). With regard to the other side chain oxysterols physiologically present in human blood, namely 24OHC and 25OHC, only a slight but significant decrease was observed in all three of the infected groups, with the only exception of a modest but significant increase of 25OHC in the PACP group. No correlation at all was observed between 24OHC and 25OHC serum levels and the severity of the disease.

Opposite to that of side chain oxysterols was the behaviour in COVID-19 shown by the two B-ring non enzymatic oxysterols of major pathological meaning, namely 7βOHC and 7KC, actually recognized markers of oxidative stress [25, 26] . Serum concentration of both oxysterols showed a significant while moderate increment in severe COVID-19 patients as respect to controls (P <0.001 for both). Serum 7KC but not 7βOHC was significantly increased in the moderate COVID-19 patients as well (P = 0.002). In the SARS-CoV-2 positive but pauci-or a-symptomatic subjects, both markers of oxidative stress did not show any significant difference when compared to the control individuals ( figure 6 ).

The data reported in this study demonstrate that 27OHC blocks the replication in vitro of two human CoVs belonging to the β-coronavirus genus: SARS-CoV-2 and HCoV-OC43. These findings further confirm the broad spectrum of antiviral activity of 27OHC, which has been already demonstrated for herpes simplex virus, rhinovirus, rotavirus and papillomavirus [5] . Since all of these viruses are phylogenetically unrelated, with ample diversity in their replicative cycles and structures, it is unlikely that 27OHC targets specific functions such as viral enzymes or antireceptors. Moreover, 27OHC does not directly inactivate the viral particle as shown also in previous studies [8] (figure S1). The ability to impair viral entry and/or replication when added up to 24h before virus inoculum supports the idea that 27OHC modifies cell structures rather than targeting viral components. Indeed, the host-targeting antiviral mode of action has already been reported by Civra et al., [10] showing that 27OHC induces accumulation of cholesterol in the late endosomal compartment resulting in sequestering human rotavirus particles inside these vesicles, thereby preventing cytoplasmic viral replication. Since also CoVs entry into the host cells involves the endocytic pathway [27] [28] [29] , the anti-CoVs activity of 27OHC appears due, at least in part, to the transient modification of the endosomal membrane composition and function exerted by the oxysterol. This is especially true in case of 27OHC externally added to the cells, that is in a pharmaceutical mode, in other words as a drug product. Exogenously added 27OHC was proven to almost exclusively accumulate in lipid rafts, as opposed to oxysterols of not enzymatic origin that randomly localize in plasma membranes [12] . Thus, 27OHC is modifying structure and most likely function of these crucial membrane lipid-protein clusters, where by the way the ACE-2 receptor exploited by SARS-CoV-2 to enter the target cells is located [30] , and it certainly induces a modification of multivesicular endosome biogenesis, that by lipid rafts is regulated [31] . Further, we very recently observed in HeLa cells a significant 27OHC-dependent down-regulation of cation independent isoform of mannose-6-phosphate receptor (MPRci) [11] , a transporter located at late endosomes whose activity appears crucial for all viruses exploiting the endosomal way to enter and diffuse within cells [32] [33] [34] . All together, these facts and findings point to the inhibition of virus entry as the primary protective mechanism of 27OHC externally added to cells.

In this relation, very likely appears the involvement of redox reactions at the 27OHC concentration range proven to inhibit SARS-CoV-2 and CoV-OC43 replication, since similar oxysterol's amounts have been previously demonstrated to transiently increase the level of oxidant species in human promonocytic cells through the activation of NADPH oxidase and the modulation of mitochondrial membrane potential [35] . How such a transient oxidative imbalance exerted by 27OHC contributes to its anti-SARS-CoV-2 and anti-CoV-OC43 activity is matter of ongoing J o u r n a l P r e -p r o o f studies, that are also considering this oxysterol ability to induce autophagy [36] , a cellular degradation process in principle favouring the elimination of viral pathogens by delivering viral particles for lysosomal degradation and closely interacting with innate immunity [37] . Notably, the pro-autophagic effect of 27OHC observed in human promonocytic cells was abolished by cell pretratment with a selective NADPH oxidase inhibitor [36] .

27OHC has also been shown to modulate the immune-response to infections by increasing the expression of dendritic cell markers and MHC classes I and II molecules [38, 39] or by activating the TLR4/NF-κB signalling pathway [40] , or to induce expression, synthesis and release of Heat Shock Protein 60 (HSP60) [41] , a chaperone molecule of mitochondrial origin, recognized to play an important role in the intercellular immune network [42] . Finally, all immune cells express the oxysterols' receptors Liver X (LXRs) [43] , but how their activity could be modulated by molecules like 27OHC still has to be elucidated.

The physiological nature of 27OHC and its potential role as first line constitutive effector of the antiviral defences of human body prompted us to analyse the 27OHC serum levels in COVID-19 patients at different stages of disease progression.

Standard laboratory findings achieved in hospitalized patients were consistent with previous reports on COVID-19 [44] [45] [46] [47] . Of particular interest were the low or very low serum cholesterol levels observed in moderate and severe COVID-19 patients, respectively (figure 4 and table S1), indicating a severe impairment of cholesterol metabolism. Serum cholesterol has just been shown to be significantly decreased in COVID-19 patients in direct relation with the severity of the disease, with data highly consistent with those obtained in this study [48] , while the reduction of the main sterol precursors of cholesterol in COVID-19 has not been reported in the literature yet. A big impairment of cholesterol metabolism, at least in severe COVID-19 patients, was actually expected since a net reduction of cholesterol biosynthesis was described as associated with massive acute phase reaction [49] . Certainly remarkable is the fact that, despite such a profound derangement of cholesterol metabolism in COVID-19, of the three cholesterol oxidation products of enzymatic origin physiologically present in human blood, i.e. 24OHC, 25OHC and 27OHC, only 27OHC showed a pronounced decrease whose intensity tightly correlated to the disease progression ( figure   5 ).

The drop in 27OHC serum concentration appeared to be a specific event, since 24OHC was slightly reduced only in moderate (P = 0.036) and severe (P = 0.029) COVID-19 cases, while 25OHC exhibited a small but significant decline only in severe patients (P = 0.018) and it was even slightly increased in the PACP group ( P= 0.033 compared to controls, P < 0.001 compared to 

Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): A review

Cellular targets for the treatment of Flavivirus infections

Integration of metabolism and inflammation by lipid-activated nuclear receptors

LXR signaling couples sterol metabolism to proliferation in the acquired immune response

Oxysterols: an emerging class of broad spectrum antiviral effectors

25-Hydroxycholesterol protects host against Zika virus infection and its associated microcephaly in a mouse model

Inhibition of pathogenic non-enveloped viruses by 25-hydroxycholesterol and 27-hydroxycholesterol

Inhibition of herpes simplex-1 virus replication by 25-hydroxycholesteroland 27-hydroxycholesterol

25-Hydroxycholesterol and 27-hydroxycholesterol inhibit human rotavirus infection by sequestering viral particles into late endosomes

Modulation of cell proteome by 25-hydroxycholesterol and 27-hydroxycholesterol: A link between cholesterol metabolism and antiviral defense. Free Radic

Absence of correlation between oxysterol accumulation in lipid raft microdomains, calcium increase, and apoptosis induction on 158N murine oligodendrocytes

27-Hydroxycholesterol impairs plasma membrane lipid raft signaling as evidenced by inhibition of IL6-JAK-STAT3 signaling in prostate cancer cells

Oxysterols as biomarkers in neurodegenerative diseases

Genetic connections between neurological disorders and cholesterol metabolism

Antiviral oxysterols are present in human milk at diverse stages of lactation

Repurposing of Miglustat to inhibit the coronavirus Severe Acquired Respiratory Syndrome SARS-CoV-2

Isolation and full-length genome characterization of SARS-CoV-2 from COVID-19 cases in northern Italy

Highly sulfated K5 Escherichia Coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study

Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19

Characteristics of COVID-19 infection in Beijing

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy. Free Radic

Cholesterol and related sterols autoxidation. Free Radic

Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted

SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway

Coronavirus membrane fusion mechanism offers a potential target for antiviral development

Lipid rafts are involved in SARS-CoV entry into Vero E6 cells

Lipid sorting and multivesicular endosome biogenesis

Mannose 6-phosphate receptor targeting and its applications in human diseases

Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis

Most rotavirus strains require the cation-independent mannose-6-phosphate receptor, sortilin-1, and cathepsins to enter cells

Survival signaling elicited by 27-hydroxycholesterol through the combined modulation of cellular redox state and ERK/Akt phosphorylation, Free Radic

The role of autophagy in survival response induced by 27-hydroxycholesterol in human promonocytic cells

Crosstalk between autophagy and type I interferon responses in innate antiviral immunity

Oxysterols induce transition of monocytic cells to phenotypically mature dendritic cell-like cells

Cyclosporin A inhibits differentiation and activation of monocytic cells induced by 27-hydroxycholesterol

Relation between TLR4/NF-κB signaling pathway activation by 27-hydroxycholesterol and 4-hydroxynonenal, and atherosclerotic plaque instability

27-Hydroxycholesterol upregulates the production of heat shock protein 60 of monocytic cells

The HSP60 immune system network

LXR and PPAR as integrators of lipid homeostasis and immunity

A New Predictor of Disease Severity in Patients with COVID-19 in Wuhan

The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy

Hypolipidemia is associated with the severity of COVID-19

Changes in the concentration and composition of plasma lipoproteins during the acute phase response

The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response

Are side-chain oxidized oxysterols regulators also in vivo?

The common cold